- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 493/08 - Bridged systems
Patent holdings for IPC class C07D 493/08
Total number of patents in this class: 902
10-year publication summary
|
81
|
53
|
61
|
79
|
70
|
49
|
49
|
60
|
50
|
56
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| VALO Health, Inc. | 176 |
37 |
| Novartis AG | 10635 |
21 |
| Lixte Biotechnology, Inc. | 63 |
21 |
| Pfizer Inc. | 3403 |
14 |
| Eisai R&D Management Co., Ltd. | 1208 |
14 |
| BASF Agro B.V. | 202 |
13 |
| President and Fellows of Harvard College | 6028 |
12 |
| Vanderbilt University | 1931 |
12 |
| Syngenta Limited | 448 |
10 |
| Gilead Sciences, Inc. | 2083 |
10 |
| Bristol-myers Squibb Company | 4833 |
9 |
| Janssen Pharmaceutica N.V. | 3351 |
9 |
| Abbvie Inc. | 1813 |
9 |
| Tokyo Ohka Kogyo Co., Ltd. | 1551 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2897 |
9 |
| F. Hoffmann-La Roche AG | 7931 |
8 |
| Purdue Research Foundation | 3715 |
8 |
| JNC Corporation | 1506 |
8 |
| JNC Petrochemical Corporation | 327 |
8 |
| Sunshine Lake Pharma Co., Ltd. | 600 |
8 |
| Other owners | 653 |